CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
• Corporate Office: - Empire House, 3''^a Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2020

Revenue from Operations 2020 2019 2020 2019 2020 2020 2019 2020 2020 2019 2020 2020 2019 2020 20		s in Thousand Year Ended 31st March 2020 Audited - 9,967 9,967 1,813 231
No. Particulars 2020 2020 2019 2020 2020 2019 2020 2	2019 Unaudited 5,610 5,610 - - - 835 - 1,487	2020 Audited 9,967 9,967 1,813
Revenue from Operations	5,610 5,610 - - - - 835 - 1,487	9,967 9,967 1,813
Other Income	5,610 - - - 835 - 1,487	9,967 - - - 1,813
Other Income	5,610 - - - 835 - 1,487	9,967 - - - 1,813
III Total Revenue (I + II) 1,428 1,563 2,779 2,991 IV Expenses	5,610 - - - 835 - 1,487	9,967 - - - 1,813
IV Expenses	- - - 835 - 1,487	- - - 1,813
2 Purchase of Stock-in-Trade	- - 835 - 1,487	1,813
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade Stock-in-Trade Changes Changes	- 835 - 1,487	1,813
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade Stock-in-Trade Changes Changes	- 835 - 1,487	1,813
(4) Employee Benefits Expenses 216 245 430 461 (5) Depreciation and Amortisation Expenses (6) Administrative and Other Expenses 200 431 564 631 i) Professional Charges ii) Professional Charges iii) Travellling Expenses iii) Travellling Expenses	1,487	
(5) Depreciation and Amortisation Expenses - - - - -	1,487	231
i) Professional Charges	, -	
ii) Annual Listing Fees	-	2,982
iii) Travellling Expenses		-
iv) Postal Charges	-	-
Total Expenses	1	-
Total Expenses	1	-
V Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV) Exceptional Items 1,012 887 1,785 1,899 VI Exceptional Items	-	-
Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	2,322	5,026
VI Exceptional Items - - - -	2.000	4.041
VII Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI) 1,012 887 1,785 1,899 VIII Extra Ordinary Items	3,288	4,941
VII Extra Ordinary Items - - - - IX Profit/(Loss) before Tax (VII-VIII) 1,012 887 1,785 1,899 X Tax Expenses (1) Current Tax - - (2) Tax Adjustment Previous Year - 56 - 56 (3) Deffered Tax - XI Profit/(Loss) for the period from continuing operations (IX - XI Profit/(Loss) from discontinuing operations - XII Profit/(Loss) from discontinuing operations - XIII Tax Expenses of discontinuing operations - XIV Profit/(Loss) from discontinuing operations (after tax) (XII - XIV Profit/(Loss) for the period (XI - XIV) 1,012 831 1,785 1,843	-	-
VI Extra Ordinary Items	3,288	4,941
IX Profit/(Loss) before Tax (VII-VIII) 1,012 887 1,785 1,899 X Tax Expenses	3,200	4,941
X Tax Expenses	-	_
(1) Current Tax	3,288	4,941
(2) Tax Adjustment Previous Year		
(3) Deffered Tax	-	760
No. Profit/(Loss) for the period from continuing operations (IX - X) No. No.	-	30
X Profit/(Loss) from discontinuing operations - - - XII Profit/(Loss) from discontinuing operations - - - XIII Tax Expenses of discontinuing operations - - - XIV Profit/(Loss) from discontinuing operations (after tax) (XII - XIII XV Profit/(Loss) for the period (XI - XIV) 1,012 831 1,785 1,843	-	-
XIII Tax Expenses of discontinuing operations - - - - XIV Profit/(Loss) from discontinuing operations (after tax) (XII - - - XIII XV Profit/(Loss) for the period (XI - XIV) 1,012 831 1,785 1,843	3,288	4,151
XIV Profit/(Loss) from discontinuing operations (after tax) (XII - XIII) - - - -	-	-
XIII) XIV Profit/(Loss) for the period (XI - XIV) 1,012 831 1,785 1,843	-	-
	-	-
, , ,	3,288	4,151
XVI Other Comprehensive Income	0,200	4,101
A (i) Itmes that will not be reclassified to profit or loss		
(ii) Income rax relating to items that will not be reclassified to		
profit or loss		
B (i) Itmes that will not be reclassified to profit or loss		
(ii) Income rax relating to items that will not be reclassified to		
XVII Total Comprehensive Income for the period (XV+XVI)	-	
	2 000	4
(Comprising Profit (Loss) and Other Comprehensive Income 1,012 831 1,785 1,843 for the period	3,288	4,151
XVIII Earnings per Share : (1) Basic 0.67 0.55 1.19 1.23	2.19	2.77
(1) Dash (2) Diluted	4.19	4.11

Notes:

- 1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- 2 The above Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2020 have been reviewed by the Audit Committee in their Meeting held on 19.10.2020 and approved by the Board of Directors of its Meeting held on 19.10.2020. The Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place: Mumbai Date: 19.10.2020



For Chemo Phorma Laboratories Limite

Shreeniwas Somani Director (DIN - 00077939)

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301 • Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2020

(Rs. In Thousand)

		STANDALONE					
PARTICULARS	IINAUDIMED OUADMED ENDED			UNAUDITED HALF		AUDITED	
PARTICULARS	UNAUDITED QUARTER END		K ENDED	YEAR ENDED		YEAR ENDED	
	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020	
Reconciliation of Profit After Tax as reported earlier:							
Net Profit / (Loss) for the Period (as per AS)	1,012.00	831.00	1,785.00	1,843.00	3,288.00	4,151.00	
Benefit / (Charge):	-	-	-	-	-	-	
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-	
Impact of Fair Valuation of Financial Instruments	-	-	-	-	-	-	
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	-	
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-	
Net Profit / (Loss) for the Period (as per AS)	1,012.00	831.00	1,785.00	1,843.00	3,288.00	4,151.00	

eniwas Somani Director

(DIN - 00077939)

Mumbai, 19.10.2020

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE CASH FLOW STATEMENT FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER 2020

(Rupees in thousands)

	Half Year Ended	Year Ended	
PARTICULARS	30.09.2020	31.03.2020	
TARTECDARS	Unaudited	Audited	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before tax and extraordinary items	1,899	4,941	
Adjustement for			
Depreciation	-	231	
Liabilities written back	-	-	
Dividend received	-	(5)	
Interest received	(2,991)	(9,962)	
Operating profit before working capital changes	(1,092)	(4,795)	
Adjustement for			
Increase (Decrease) in other Current Liabilities	(224)	1,295	
Decrease (increase) in Current Assets	(2,423)	54,711	
Increase in Fixed Assets	(14)	(948)	
Increase in Loan Given	-	(1,150)	
Cash Generated From Operation	(2,661)	53,908	
Taxes Paid	(56)	(790)	
A. Cash Flow From Operating Activities	(3,809)	48,323	
B. CASH FLOW FROM INVESTING ACTIVITIES			
Dividend received	-	5	
Interest received	2,991	9,962	
Decrease in Investment	-	132	
Cash Flow From Investing Activities	2,991	10,099	
C. CASH FLOW FROM FINANCING ACTIVITIES			
Interest Paid	-	_	
Long Term / Short Term Borrowings	-	_	
Short Term Investment / Loan	_	_	
Cash Flow From Financing Activities	-	-	
Net increase/(decrease) in cash and cash Equivalents	(818)	58,422	
Opening balance of Cash and Cash Equivalents	88,084	29,662	
Closing Balance Of Cash and Cash Equivalents	87,266	88,084	

SOMBAY OF STREET

Place: Mumbai

Date: 19.10.2020

For Chemo Pharma Laboratories Limited

Shreeniwas Somani Director

(DIN - 00077939)

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER, 2020

(Rupees in Thousands)

Sr. No.	PARTICULARS	As at 30.09.2020 Unaudited	As at 31.03.2020 Audited
1	<u>ASSETS</u>		
1	Non-Current Assets		
	(A) Property, Plant & Equipment	761	747
	(B) Financial Assets		
	(i) Investment	237	237
	(ii) Long Term Loans	19,568	19,568
	Total Non-Current Assets	20,566	20,552
2	Current Assets		
	(i) Cash & Cash Equivalents	87,266	88,084
	(ii) Loans	3,444	1,021
	Total Current Assets	90,710	89,105
	TOTAL ASSETS	111,276	109,657
2	EQUITY AND LIABILTIES		
1	<u>Equity</u>		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity (Reserve & Surplus)	94,290	92,447
	Total Equity	109,290	107,447
2	<u>Liabilities</u>		
1	Non-Current Liabilities	-	-
2	Current Liabilities		
	(i) Borrowings	-	-
	(ii) Other Current Liabilities	1,986	1,450
	(iii) Provisions		760
	Total Current Liabilities	1,986	2,210
	TOTAL EQUITY AND LIABILITIES	111,276	109,657

By Order of the Board

Place : Mumbai
Date : 19.10.2020

For Chemo Pharma Laboratories Limited

Shreeniwas Somani Director

(DIN - 00077939)